Are you over 18 and want to see adult content?
More Annotations
![A complete backup of teachingtreasures.com.au](https://www.archivebay.com/archive5/images/404002ca-4e8d-4585-93df-82b6e1e3a667.png)
A complete backup of teachingtreasures.com.au
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://converse.co.jp](https://www.archivebay.com/archive6/images/dcfe0a83-8c29-482d-86b0-da2cacd76a1b.png)
A complete backup of https://converse.co.jp
Are you over 18 and want to see adult content?
![A complete backup of https://blazingminds.co.uk](https://www.archivebay.com/archive6/images/dfa38666-6055-4b3b-b7f4-7c2d0268bbed.png)
A complete backup of https://blazingminds.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://aids2020.org](https://www.archivebay.com/archive6/images/c9778e6c-90fe-4583-8671-a619cb2d75c1.png)
A complete backup of https://aids2020.org
Are you over 18 and want to see adult content?
![A complete backup of https://carlasonheim.com](https://www.archivebay.com/archive6/images/5cbf539d-92ac-4fd9-af16-4dde540c4cc8.png)
A complete backup of https://carlasonheim.com
Are you over 18 and want to see adult content?
![A complete backup of https://carkeys.co.uk](https://www.archivebay.com/archive6/images/5f2cff55-fa57-46ab-b314-971fcedb98f1.png)
A complete backup of https://carkeys.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://pilarjerico.com](https://www.archivebay.com/archive6/images/cd5bfa76-af7f-4bcd-8f36-659f79e73dcf.png)
A complete backup of https://pilarjerico.com
Are you over 18 and want to see adult content?
![A complete backup of https://foodshouldtastegood.com](https://www.archivebay.com/archive6/images/d4487a8e-c406-4abe-ab81-3a3ccb6085dd.png)
A complete backup of https://foodshouldtastegood.com
Are you over 18 and want to see adult content?
![A complete backup of https://luigi-bevilacqua.com](https://www.archivebay.com/archive6/images/494eb1e0-c096-49db-acdf-57a7f2cb47d7.png)
A complete backup of https://luigi-bevilacqua.com
Are you over 18 and want to see adult content?
![A complete backup of https://lineadirecta.com](https://www.archivebay.com/archive6/images/d959107c-5c8c-4da0-a23a-ee6f0e0e3b38.png)
A complete backup of https://lineadirecta.com
Are you over 18 and want to see adult content?
![A complete backup of https://englishclub.com](https://www.archivebay.com/archive6/images/cbc0bed7-e673-45b3-823f-e55f44fa3941.png)
A complete backup of https://englishclub.com
Are you over 18 and want to see adult content?
![A complete backup of https://caferule.com](https://www.archivebay.com/archive6/images/ede59c70-160e-47d2-956f-224a9ecd18b5.png)
A complete backup of https://caferule.com
Are you over 18 and want to see adult content?
![A complete backup of https://orderdrugsonline247.com](https://www.archivebay.com/archive6/images/5e032f8f-2ca2-4c5d-acbc-e74c4f7c7c26.png)
A complete backup of https://orderdrugsonline247.com
Are you over 18 and want to see adult content?
Text
ENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma JUST HOW SADLY MISGUIDED IS THE FDA ON ADUCANUMAB Editor. The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands NOVARTIS PLOTS ‘NEXT FRONTIER’ OF MS TREATMENT A couÂple of months afÂter getÂting its self-adÂminÂisÂtered mulÂtiÂple scleÂroÂsis drug KesÂimpÂta cleared by EU regÂuÂlaÂtors, NoÂvarÂtis has found what it beÂlieves is “the EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap ENDPOINTS AT #ASCO21 ASCO highlights: The biggest breakthroughs; the worst setbacks. Every year the biopharma industry turns to ASCO to help define where cancer drug R&D is headed. Endpoints News will bring together a group of experts to discuss the most important presentations at the conference, with insights on the winners and losers at ASCO 21. TEVA CEO KÃ…RE SCHULTZ SEES A 35% RAISE DESPITE THE COMPANY The new awards helped boost Schultz’s pay by nearÂly 36% year over year, when he reÂceived $11.6 milÂlion in 2019. His 2020 packÂage is still a far cry from his first year steerÂing TeÂva EDUARDO BRAVO RETURNS TO BRING EUROPEAN BIOTECH IN ON THEAUTHOR: JASONMAST
The last year's SPAC boom has been dominated so far by US-based VCs. Now a prominent European biotech executive and a couple investors aregetting
ASTELLAS OUTLINES ANOTHER FIVE-YEAR PLAN; BAYER’S VC ARM Three years after Astellas unveiled its last five-year plan, the Japanese pharma is unveiling another. The new blueprint, announced Wednesday, is less sweeping orKYLE BLANKENSHIP
kyle@endpointsnews.com @ka_blankenship. Kyle Blankenship on LinkedIn. A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor SAY GOODBYE TO TOCAGEN, STRUGGLING BRAIN CANCER BIOTECH TO In fact, paÂtients on the conÂtrol arm lived a month longer on avÂerÂage than paÂtients on the drug arm, 12.2 vs 11.1. That comÂputÂed to a hazÂard raÂtio of 1.06 and a p-valÂue of 0.62.ENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma JUST HOW SADLY MISGUIDED IS THE FDA ON ADUCANUMAB Editor. The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands NOVARTIS PLOTS ‘NEXT FRONTIER’ OF MS TREATMENT A couÂple of months afÂter getÂting its self-adÂminÂisÂtered mulÂtiÂple scleÂroÂsis drug KesÂimpÂta cleared by EU regÂuÂlaÂtors, NoÂvarÂtis has found what it beÂlieves is “the EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap ENDPOINTS AT #ASCO21 ASCO highlights: The biggest breakthroughs; the worst setbacks. Every year the biopharma industry turns to ASCO to help define where cancer drug R&D is headed. Endpoints News will bring together a group of experts to discuss the most important presentations at the conference, with insights on the winners and losers at ASCO 21. TEVA CEO KÃ…RE SCHULTZ SEES A 35% RAISE DESPITE THE COMPANY The new awards helped boost Schultz’s pay by nearÂly 36% year over year, when he reÂceived $11.6 milÂlion in 2019. His 2020 packÂage is still a far cry from his first year steerÂing TeÂva EDUARDO BRAVO RETURNS TO BRING EUROPEAN BIOTECH IN ON THEAUTHOR: JASONMAST
The last year's SPAC boom has been dominated so far by US-based VCs. Now a prominent European biotech executive and a couple investors aregetting
ASTELLAS OUTLINES ANOTHER FIVE-YEAR PLAN; BAYER’S VC ARM Three years after Astellas unveiled its last five-year plan, the Japanese pharma is unveiling another. The new blueprint, announced Wednesday, is less sweeping orKYLE BLANKENSHIP
kyle@endpointsnews.com @ka_blankenship. Kyle Blankenship on LinkedIn. A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor SAY GOODBYE TO TOCAGEN, STRUGGLING BRAIN CANCER BIOTECH TO In fact, paÂtients on the conÂtrol arm lived a month longer on avÂerÂage than paÂtients on the drug arm, 12.2 vs 11.1. That comÂputÂed to a hazÂard raÂtio of 1.06 and a p-valÂue of 0.62. A GENE THERAPY BIOTECH IS BURSTING ONTO THE SCENE WITH 12 1 day ago · In downÂtown LowÂell, MA, tucked inÂto one of the counÂtry’s oldÂest surÂvivÂing texÂtile mill comÂplexÂes is a new biotech toilÂing away on next-gen CNS therÂaÂpies for seÂvere US TO SHELL OUT $1.2B FOR SUPPLIES OF MERCK’S POTENTIAL 1 day ago · Pending positive Phase III results, the US government said early Wednesday that it will pay Merck $1.2 billion for about 1.7 million courses of its Covid-19 antiviral pill molnupiravir. Merck VERTEX STRIKES OUT ON ITS LATEST BIG SHOT AT A RARE 9 hours ago · It’s been sevÂerÂal months since VerÂtex culled one of its small molÂeÂcules for alÂpha-1 anÂtitÂrypsin deÂfiÂcienÂcy (AATD), takÂing a big hit afÂter evÂiÂdence oflivÂer dam
PFIZER ROLLS OUT NEXT-GEN PNEUMOCOCCAL VACCINE WITH FDA 1 day ago · Merck and Pfizer have been locked in a yearslong battle for a next-gen pneumococcal vaccine winner, with the latter looking to one-up — or should we A SECOND ADCOMM MEMBER ABANDONS HIS POST IN AFTERMATH OF 14 hours ago · The FDA lost another member of its Peripheral and Central Nervous System Drugs Advisory Committee on Wednesday, as Mayo Clinic neurologist David Knopman hit the exit over the agency’sdecision
CITING ‘EXCESSIVE’ EXECUTIVE COMPENSATION, ADVISORY FIRMS 19 hours ago · GrumÂbles have grown loudÂer at ReÂgenÂeron in reÂcent months over the pay packÂages reÂceived by top exÂecs, and now two large adÂviÂsoÂry firms are recÂomÂmendÂingshareÂholdÂers
UPDATED: FDA REJECTS GOOGLE’S PUSH TO ADD VIRTUAL EXAM FOR The FDA recently shot down an attempt by Google's Verily to qualify the addition of a virtual motor exam for Parkinson’s disease to its smartwatch. In its rejection letter, the agency said the BRISTOL MYERS’ CAR-T BREYANZI BUSTS OUT A WIN IN EARLIER 15 hours ago · Despite being third to the field in B cell lymphoma, Bristol Myers Squibb has repeatedly argued its CAR-T Breyanzi could have the juice to overtake its older competitors. Going into earlierlines
WILL BIOGEN EVER PUBLISH THE TRIAL RESULTS FOR ITS NEW 1 day ago · Usually when a new drug is approved by the FDA, physicians who might use that drug can turn to the medical literature for a deeper understanding of who UPDATED: J&J BREAKS OFF ALLIANCE WITH ARGENX, DROPPING Over the past two and a half years, J&J scientists have rolled up their sleeves alongside partners at argenx to get a closer look at the anti-CD70 antibody cusatuzumab, chasing what a top execENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap BIDEN HHS SEEKS TO DISMISS PHRMA’S LAWSUIT TO STOP As the FDA has yet to authorize any state plans to import prescription drugs from Canada, the Biden administration called on the US DistrictCourt
EXCLUSIVE: HELSINN CHIEF RICCARDO BRAGLIA SPELLS OUT A Late on Friday, as the biopharma industry in the US was making a rush to the exits for a 3-day weekend, BridgeBio put out word that the FDAhad come through on
REGENERON’S GOLDEN GOOSE EYLEA MAY STAVE OFF BIOSIMILAR Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of BOEHRINGER EMBARKS ON A PHIII ODYSSEY FOR A FAILED In the 8 months since researchers at Boehringer Ingelheim laid claim to a Phase II win for their schizophrenia drug BI 425809, the project team has been busily working up an ambitious Phase III CMC HOLDUP DELAYS IOVANCE FILING AGAIN CEO Maria Fardis highÂlightÂed the fact that liÂfileuÂcel, which is iniÂtialÂly beÂing deÂvelÂoped for PD-1 reÂfracÂtoÂry melanoma, repÂreÂsentÂed the first cell therÂaÂpy in solENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap BIDEN HHS SEEKS TO DISMISS PHRMA’S LAWSUIT TO STOP As the FDA has yet to authorize any state plans to import prescription drugs from Canada, the Biden administration called on the US DistrictCourt
EXCLUSIVE: HELSINN CHIEF RICCARDO BRAGLIA SPELLS OUT A Late on Friday, as the biopharma industry in the US was making a rush to the exits for a 3-day weekend, BridgeBio put out word that the FDAhad come through on
REGENERON’S GOLDEN GOOSE EYLEA MAY STAVE OFF BIOSIMILAR Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of BOEHRINGER EMBARKS ON A PHIII ODYSSEY FOR A FAILED In the 8 months since researchers at Boehringer Ingelheim laid claim to a Phase II win for their schizophrenia drug BI 425809, the project team has been busily working up an ambitious Phase III CMC HOLDUP DELAYS IOVANCE FILING AGAIN CEO Maria Fardis highÂlightÂed the fact that liÂfileuÂcel, which is iniÂtialÂly beÂing deÂvelÂoped for PD-1 reÂfracÂtoÂry melanoma, repÂreÂsentÂed the first cell therÂaÂpy in sol ON A CONTINUED HUNT FOR PARKINSON’S BREAKTHROUGHS, ABBVIE 12 hours ago · Two and a half years ago, AbbVie’s venture arm quietly co-led a $23 million Series A for Rheostat Therapeutics, mostly betting on the idea of restoring clearance pathways that arecentral to
WHITE HOUSE LAYS OUT SPRAWLING NEW PLAN TO SHORE UP PHARMA 1 day ago · The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech a ENDPOINTS NEWS POLL: LET’S GET YOUR OPINION ON THAT 1 day ago · The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech a SPRINGWORKS AND SEAGEN TEAM UP IN MULTIPLE MYELOMA; MERCK SpringÂWorks has a new colÂlabÂoÂraÂtion, and it’s one with a promiÂnent pharÂma partÂner. The ConÂnectiÂcut biotech is teamÂing up with Seagen on a new clinÂiÂcal triÂal to eval JUST HOW SADLY MISGUIDED IS THE FDA ON ADUCANUMAB The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and handsthe large biotech a
TRAILING THE BIG PHARMA PLAYERS, A LESSER KNOWN BCMA CAR-T 1 day ago · Bristol Myers Squibb and bluebird cleared the first BCMA CAR-T therapy for multiple myeloma patients back in March, and J&J and their partners at Legend Biotech aren’t far behind. Now, a lesser KEEN TO TURN A NEW PAGE, INDIVIOR BRANCHES OUT, PICKING UP 1 day ago · The deal is a culÂmiÂnaÂtion of sevÂen years of work by PiÂazÂza since his group at the NeuÂroÂcenÂtre MaÂgendie in BorÂdeaux shed light on an enÂdogeÂnous molÂeÂcule that the brain INCYTE FACES DELAY ON FDA’S JAKAFI DECISION FOR CGVHD 1 day ago · Just 10 months afÂter InÂcyte postÂed an upÂbeat asÂsessÂment for Jakafi in a Phase III for chronÂic graft-verÂsus-host disÂease, the FDA has optÂed to push back the sNÂDA to latÂer in AMID COVID-19 HUNT, PFIZER ADDS LYME DISEASE VACCINE IN In the midst of their $500 million program to build a Covid-19 vaccine with BioNTech, Pfizer has announced a sizable deal to commercialize a vaccine for a far different disease. Pfizer and Valneva HOPING TO CHALLENGE BLOCKBUSTER BREAST CANCER FRANCHISES 1 day ago · For the last sevÂerÂal years, an unÂder-the-radar chalÂlenger to Big PharÂma’s breast canÂcer franÂchisÂes has been workÂing on an anÂtiÂbody drug conÂjuÂgate inÂvolvÂing HerENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap BIDEN HHS SEEKS TO DISMISS PHRMA’S LAWSUIT TO STOP As the FDA has yet to authorize any state plans to import prescription drugs from Canada, the Biden administration called on the US DistrictCourt
EXCLUSIVE: HELSINN CHIEF RICCARDO BRAGLIA SPELLS OUT A Late on Friday, as the biopharma industry in the US was making a rush to the exits for a 3-day weekend, BridgeBio put out word that the FDAhad come through on
REGENERON’S GOLDEN GOOSE EYLEA MAY STAVE OFF BIOSIMILAR Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of BOEHRINGER EMBARKS ON A PHIII ODYSSEY FOR A FAILED In the 8 months since researchers at Boehringer Ingelheim laid claim to a Phase II win for their schizophrenia drug BI 425809, the project team has been busily working up an ambitious Phase III CMC HOLDUP DELAYS IOVANCE FILING AGAIN CEO Maria Fardis highÂlightÂed the fact that liÂfileuÂcel, which is iniÂtialÂly beÂing deÂvelÂoped for PD-1 reÂfracÂtoÂry melanoma, repÂreÂsentÂed the first cell therÂaÂpy in solENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap BIDEN HHS SEEKS TO DISMISS PHRMA’S LAWSUIT TO STOP As the FDA has yet to authorize any state plans to import prescription drugs from Canada, the Biden administration called on the US DistrictCourt
EXCLUSIVE: HELSINN CHIEF RICCARDO BRAGLIA SPELLS OUT A Late on Friday, as the biopharma industry in the US was making a rush to the exits for a 3-day weekend, BridgeBio put out word that the FDAhad come through on
REGENERON’S GOLDEN GOOSE EYLEA MAY STAVE OFF BIOSIMILAR Almost 10 years have passed since its first FDA approval and Regeneron’s macular degeneration injection Eylea continues to pile up sales to the tune of BOEHRINGER EMBARKS ON A PHIII ODYSSEY FOR A FAILED In the 8 months since researchers at Boehringer Ingelheim laid claim to a Phase II win for their schizophrenia drug BI 425809, the project team has been busily working up an ambitious Phase III CMC HOLDUP DELAYS IOVANCE FILING AGAIN CEO Maria Fardis highÂlightÂed the fact that liÂfileuÂcel, which is iniÂtialÂly beÂing deÂvelÂoped for PD-1 reÂfracÂtoÂry melanoma, repÂreÂsentÂed the first cell therÂaÂpy in sol WHITE HOUSE LAYS OUT SPRAWLING NEW PLAN TO SHORE UP PHARMA 1 day ago · As the US increasingly relies on foreign drug and active pharmaceutical ingredient (API) manufacturing, particularly from China and India, the Biden-Harris Administration early Tuesday morning SPRINGWORKS AND SEAGEN TEAM UP IN MULTIPLE MYELOMA; MERCK 1 day ago · SpringÂWorks has a new colÂlabÂoÂraÂtion, and it’s one with a promiÂnent pharÂma partÂner. The ConÂnectiÂcut biotech is teamÂing up with Seagen on a new clinÂiÂcal triÂal toeval
ENDPOINTS NEWS POLL: LET’S GET YOUR OPINION ON THAT 1 day ago · The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech a INCYTE FACES DELAY ON FDA’S JAKAFI DECISION FOR CGVHD 22 hours ago · Just 10 months afÂter InÂcyte postÂed an upÂbeat asÂsessÂment for Jakafi in a Phase III for chronÂic graft-verÂsus-host disÂease, the FDA has optÂed to push back the sNÂDA to latÂer in TRAILING THE BIG PHARMA PLAYERS, A LESSER KNOWN BCMA CAR-T 1 day ago · Bristol Myers Squibb and bluebird cleared the first BCMA CAR-T therapy for multiple myeloma patients back in March, and J&J and their partners at Legend Biotech aren’t far behind. Now, a lesser JUST HOW SADLY MISGUIDED IS THE FDA ON ADUCANUMAB 1 day ago · The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech a AMID COVID-19 HUNT, PFIZER ADDS LYME DISEASE VACCINE IN In the midst of their $500 million program to build a Covid-19 vaccine with BioNTech, Pfizer has announced a sizable deal to commercialize a vaccine for a far different disease. Pfizer and Valneva NOVO NORDISK SCORES A WIN FOR SEMAGLUTIDE IN OBESITY 1 day ago · Novo Nordisk pulled a highly anticipated win for its GLP-1 therapy semaglutide in obesity on Friday, becoming the first company to get a chronic weight management drug for adults pastregulators
HOPING TO CHALLENGE BLOCKBUSTER BREAST CANCER FRANCHISES 1 day ago · For the last sevÂerÂal years, an unÂder-the-radar chalÂlenger to Big PharÂma’s breast canÂcer franÂchisÂes has been workÂing on an anÂtiÂbody drug conÂjuÂgate inÂvolvÂing Her FDA LETS BLUEBIRD RESUME TRIALS FOR SICKLE CELL GENE 1 day ago · BlueÂbird bio anÂnounced that the FDA has liftÂed its holds on clinÂiÂcal triÂals for their gene therÂaÂpies for sickÂle disÂease and beÂta-thaÂlassemia, endÂing a 4-month sagathat
ENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma NOVARTIS PLOTS ‘NEXT FRONTIER’ OF MS TREATMENT A couÂple of months afÂter getÂting its self-adÂminÂisÂtered mulÂtiÂple scleÂroÂsis drug KesÂimpÂta cleared by EU regÂuÂlaÂtors, NoÂvarÂtis has found what it beÂlieves is “the EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap BIDEN HHS SEEKS TO DISMISS PHRMA’S LAWSUIT TO STOP As the FDA has yet to authorize any state plans to import prescription drugs from Canada, the Biden administration called on the US DistrictCourt
ENDPOINTS WEBINARSENDPOINTS NEWS BIOTECHENDPOINTS NEWS LOGO Endpoints Webinars. Life sciences marketers work with long sales cycles and products that require market education — which make webinars one of the most essential tools in the biopharma demand generation toolbox. Endpoints webinars are a turn-key solution — let us handle the audience generation, content, marketing, and tech. MAX GELMAN – ENDPOINTS NEWSMAKSIM GELMANMAKSIM GELMAN CRIME SCENESMAKSIM GELMAN IN PRISONMAKSIM GELMAN NOWMAKSIM GELMAN STABBING SPREEMAKSIM GELMAN WIKIPEDIA Max hails from New Jersey and spent several years of baseball reporting and editing. Over the course of two seasons, Max covered the St. Louis Cardinals, Colorado Rockies and Chicago White Sox for AS FEARS MOUNT OVER J&J AND ASTRAZENECA, NOVAVAX ENTERS A As concerns rise around the J&J and AstraZeneca vaccines, global attention is increasingly turning to the little, 33-year-old, productless, bankruptcy-flirting biotech that could: Novavax. In theKYLE BLANKENSHIP
kyle@endpointsnews.com @ka_blankenship. Kyle Blankenship on LinkedIn. A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor TONIX CRASHES ON PHIII PTSD FAILURE, SENDING STOCK TO THETONIX PHARMACEUTICALS STOCKTONIX STOCK FORECASTTONIX NEWSTONIX PHARMACEUTICALS HOLDING CORP TNXPTONIX PHARMACEUTICALS MESSAGE BOARD After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company’s stock AFTER LEAVING WALL STREET TO LAUNCH A GENE THERAPY UPSTART AfÂter leavÂing Wall Street to launch a gene therÂaÂpy upÂstart, Rachel McMinn nabs $115M to driÂve her first canÂdiÂdate to theclinÂic
ENDPOINTS NEWS
Subscriptions. ENDPOINTS NEWS by John Carroll & team — all the news at 11:30am ET. EARLY EDITION by Arsalan Arif — news and links at 7:15am ET. ENDPOINTS MANUFACTURING Weekly biopharma NOVARTIS PLOTS ‘NEXT FRONTIER’ OF MS TREATMENT A couÂple of months afÂter getÂting its self-adÂminÂisÂtered mulÂtiÂple scleÂroÂsis drug KesÂimpÂta cleared by EU regÂuÂlaÂtors, NoÂvarÂtis has found what it beÂlieves is “the EXCLUSIVE: CARL JUNE’S TMUNITY ENCOUNTERS A LETHAL The multifaceted campaign to create a CAR-T for solid tumors has run into a lethal problem. In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap BIDEN HHS SEEKS TO DISMISS PHRMA’S LAWSUIT TO STOP As the FDA has yet to authorize any state plans to import prescription drugs from Canada, the Biden administration called on the US DistrictCourt
ENDPOINTS WEBINARSENDPOINTS NEWS BIOTECHENDPOINTS NEWS LOGO Endpoints Webinars. Life sciences marketers work with long sales cycles and products that require market education — which make webinars one of the most essential tools in the biopharma demand generation toolbox. Endpoints webinars are a turn-key solution — let us handle the audience generation, content, marketing, and tech. MAX GELMAN – ENDPOINTS NEWSMAKSIM GELMANMAKSIM GELMAN CRIME SCENESMAKSIM GELMAN IN PRISONMAKSIM GELMAN NOWMAKSIM GELMAN STABBING SPREEMAKSIM GELMAN WIKIPEDIA Max hails from New Jersey and spent several years of baseball reporting and editing. Over the course of two seasons, Max covered the St. Louis Cardinals, Colorado Rockies and Chicago White Sox for AS FEARS MOUNT OVER J&J AND ASTRAZENECA, NOVAVAX ENTERS A As concerns rise around the J&J and AstraZeneca vaccines, global attention is increasingly turning to the little, 33-year-old, productless, bankruptcy-flirting biotech that could: Novavax. In theKYLE BLANKENSHIP
kyle@endpointsnews.com @ka_blankenship. Kyle Blankenship on LinkedIn. A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor TONIX CRASHES ON PHIII PTSD FAILURE, SENDING STOCK TO THETONIX PHARMACEUTICALS STOCKTONIX STOCK FORECASTTONIX NEWSTONIX PHARMACEUTICALS HOLDING CORP TNXPTONIX PHARMACEUTICALS MESSAGE BOARD After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company’s stock AFTER LEAVING WALL STREET TO LAUNCH A GENE THERAPY UPSTART AfÂter leavÂing Wall Street to launch a gene therÂaÂpy upÂstart, Rachel McMinn nabs $115M to driÂve her first canÂdiÂdate to theclinÂic
NEWS – ENDPOINTS NEWS FraÂzier reÂloads with $1.4B to bet on 'growth buyÂout' plays — nearÂly douÂble the last fund. 2 days ago. Financing. Eye inÂjecÂtions causÂing blindÂness? FDA’s stem cell clinÂic PREMIUM – ENDPOINTS NEWS A closÂer look at the FDA’s more than 700 panÂdemÂic-reÂlatÂed record reÂquests to reÂplace onÂsite inÂspecÂtions. Let’s make that $1B-plus: AbingÂworth gathÂers more cash, this COVID-19 VACCINE FOR KIDS: FDA SPELLS OUT QUESTIONS ON 4 hours ago · NIÂAID chief AnÂthoÂny FauÂci preÂdictÂed days ago that Covid-19 vacÂcines for younger chilÂdren will be availÂable by the end of the year or earÂly next year. But whatreÂquireÂments
ENDPOINTS NEWS POLL: LET’S GET YOUR OPINION ON THAT 6 hours ago · The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech a FDA REJECTS GOOGLE’S PUSH TO ADD VIRTUAL EXAM FOR 5 hours ago · The FDA recently shot down an attempt by Google’s Verily to qualify the addition of a virtual motor exam for Parkinson’s disease to its smartwatch. In its rejection letter, theagency said the
AMID COVID-19 HUNT, PFIZER ADDS LYME DISEASE VACCINE IN In the midst of their $500 million program to build a Covid-19 vaccine with BioNTech, Pfizer has announced a sizable deal to commercialize a vaccine for a far different disease. Pfizer and Valneva INCYTE FACES DELAY ON FDA’S JAKAFI DECISION FOR CGVHD 4 hours ago · Just 10 months afÂter InÂcyte postÂed an upÂbeat asÂsessÂment for Jakafi in a Phase III for chronÂic graft-verÂsus-host disÂease, the FDA has optÂed to push back the sNÂDA to latÂer in ASTRAZENECA’S NON-PROFIT VACCINE IS, FOR NOW, COSTING THEM Vectura announced Wednesday that the private equity firm Carlyle Group agreed to buy them out for $1.4 billion, or a 32% premium on thecompany’s
JUST HOW SADLY MISGUIDED IS THE FDA ON ADUCANUMAB 22 hours ago · The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech a KEEN TO TURN A NEW PAGE, INDIVIOR BRANCHES OUT, PICKING UP 6 hours ago · The deal is a culÂmiÂnaÂtion of sevÂen years of work by PiÂazÂza since his group at the NeuÂroÂcenÂtre MaÂgendie in BorÂdeaux shed light on an enÂdogeÂnous molÂeÂcule that thebrain
* Channels
* All News
* Premium Stories
* Coronavirus
* R&D
* Pharma
* Venture
* People
* Startups
* Regulatory
* Deals
* IPOs
* China
* Cell/Gene Tx
* Bioregnum
* Peer Review
* Discovery
* Outsourcing
* AI
* Special
* Events
* Biopharma Jobs
* More
* Webinars
* Sponsored Posts
* Biotech Voices
* Advertise
* Privacy Policy
* About Us
* Help
* SUBSCRIBE
* SIGN IN
TOP STORIES
UPÂDATÂED: THREE ATÂTENÂDEES AT BIOÂGEN MEETÂING IN BOSTON TEST POSÂIÂTIVE FOR COVID-193 hours ago
R&D
'DRAÂMATÂIC TIMES': HOW DID AN $8B SURGE IN NIH GRANTS OVER FIVE YEARS CHANGE REÂSEARCH ON THE GROUND (IF AT ALL)?16 hours ago
Discovery
UPÂDATÂED: AFÂTER A TRENDÂSETÂTING ROLE IN GLOBÂAL BIOTECH VENÂTURE INÂVESTÂING, DAVID MOTT PARTS WAYS WITH NEA12 hours ago
People
Venture
MORE THAN HALF OF ITS GROSS SALES ULÂTIÂMATEÂLY WENT TO PAYÂERS AS REÂBATES, SANOFI SAYS12 hours ago
Pharma
LATEST
Most read
UPÂDATÂED: HAPÂPY ALONE QIÂAÂGEN CHANGES COURSE AFÂTER THERÂMO FISHÂER OFÂFERS TO BUY IT IN $11.5B DEAL2 days ago
Deals
NOÂBODY BUT DEERÂFIELD WANTS MELINÂTA; NOÂVARÂTIS FINDS A NEW DRUG DISÂCOVÂERY PARTÂNER12 hours ago
Protocols
MACROÂGENÂICS LOSÂES CMO JON WIGÂGINÂTON AS COMÂMERÂCIALÂIZAÂTION LOOMS12 hours ago
People
R&D
FDA REÂQUIRES BOXED WARNÂING FOR SINÂGUÂLAIR AND ITS GENERÂICS13 hours ago
Pharma
Regulatory
GSK'S EMÂMA WALMÂSÂLEY AWARDÂED £8.4M PAY PACKÂAGE AFÂTER £2.5M RISE, FIÂNALÂLY CATCHÂING UP WITH FELÂLOW PHARÂMA CEOS14 hours ago
People
UPÂDATÂED: HOW DO DEÂPRESSED RATS REÂSPOND TO PSYÂCHEÂDELICS? NEW DAÂTA OFÂFER INÂSIGHT INÂTO THE HUÂMAN EXÂPEÂRIÂENCE14 hours ago
R&D
see latest stream
People
AMÂAG CMO HITS THE EXÂIT JUST AS BIOTECH SEARCHÂES FOR NEW CEO TO RIGHT A SHIP ROCKED BY MAKÂEÂNA CONÂTROÂVERÂSYYesterday
UPÂDATÂED: VERÂTEX, SEATÂTLE GEÂNETÂICS, ALPINE WITHÂDRAW FROM INÂVESTOR CONÂFERÂENCE AS BIOTECHS BRACE FOR COROÂNÂAVIRUS3 days ago
UPÂDATÂED: AS US DIÂALS UP COROÂNÂAVIRUS REÂSPONSE, BIO TAPS VIR'S GEORGE SCANÂGOS TO HEAD COMÂMITÂTEE COÂORÂDIÂNATÂINGINÂDUSÂTRY ...
3 days ago
Startups
HEAR HEAR! EAR GENE THERÂAÂPY PLAYÂER AKÂOUÂOS DRAWS $105M INFRESH CAPÂIÂTAL
2 days ago
EX NIÂHIÂLO: TAKEÂDA LEADS $100M+ ROUND TO FUND BIOTECH'S SNEAK ATÂTACK ON TUÂMORS, PROÂPELLING NEW IL-2, CTÂLA-4 DRUGS TO ...3 days ago
JIM WILSON'S GENE THERÂAÂPY STARTÂUP PASÂSAGE BIO BUCKS MARÂKET SENÂTIÂMENTS, RAISÂING UPÂSIZED $216M IPO6 days ago
Deals
ABÂBÂVIE AND ALÂLERÂGAN FIÂNALÂLY SET (ROUGH) DATE FOR WEDÂDING AS ONE PARÂENT AGREES TO THE MATCHYesterday
UPÂDATÂED: IN POSÂSIÂBLE SIGN OF THINGS TO COME, DANIEL O’DAY’S NEW-LOOK GILEAD BETS $4.9B ON CANÂCER BIOTECH3 days ago
A NAME EMERGES OUT OF THE GILEAD M&A RUÂMOR MILL, AND IT’S ACANÂCER BIOTECH
Last week
IPOs
AS SICKÂLE CELL PAÂTIENTS FIND NEW OPÂTIONS, NEA-FOUNDÂED IMARA PITCHÂES MID-STAGE ALÂTERÂNAÂTIVE FOR $86M IPO3 weeks ago
THE RAS RUSH: REVÂOÂLUÂTION MEDÂIÂCINES BAGS REÂMARKÂABLE $238M IPO RAISE, MORE THAN DOUÂBLING ORIGÂIÂNAL GOAL3 weeks ago
PARÂTY ON: BASE EDITÂING STARTÂUP, COMÂPUÂTAÂTIONÂAL DRUG DISÂCOVÂERY EXÂPERTS AND CRO BAG CLOSE TO $2B TOÂTAL ON THEIR WAYTO ...
4 weeks ago
All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceuticaldrugs.
SUBSCRIBE NOW
PREMIUM STORIESSEE ALL THE TOP 100 BIOÂPHARÂMA VENÂTURE INÂVESTORS AT THE MEGAÂBILÂLIONS DEAL TAÂBLE3 weeks ago
Venture
THE TOP 10 BIOÂPHARÂMA PIPELINE BLOWUPS, SETÂBACKS AND SNAÂFUS FORH2 2019
4 weeks ago
Bioregnum
WEAK PIPELINE? WHY, SANOFI EXÂECS ARE SUDÂDENÂLY OVER THE MOON ABOUT THEIR PROSPECTS4 weeks ago
Bioregnum
R&D
THE POWÂER OF PRECEÂDENT: HOW A ONE-OFF DEÂCIÂSION BY JANET WOODÂCOCK ESÂTABÂLISHED AN UNÂINÂTENDÂED FAST PATHÂWAY AT THEFDA ...
Last month
Bioregnum
DON'T MISSSEE ALL
FRED HUTCHINÂSON CENÂTER INIÂTIÂATES MANDAÂTOÂRY WORK-FROM-HOME POLÂIÂCY AS OUTÂBREAK ROILS BUSIÂNESSÂES, CONÂFERÂENCES15 hours ago
Coronavirus
VILÂIÂFIED FOR HIGH DRUG PRICES, WHAT DOES THE PROFÂITABILÂIÂTY OF MAÂJOR US PHARÂMA COMÂPAÂNIES LOOK LIKE?18 hours ago
Pharma
TACKÂLING INÂHERÂITÂED BLINDÂNESS, EDÂIÂTAS AND ALÂLERÂGAN USE CRISPR FOR THE FIRST TIME IN THE HUÂMAN BODYYesterday
R&D
UPÂDATÂED: ADD TAKEÂDA AND ALÂNYÂLAM TO THE MENU OF GLOBÂAL DRUGÂMAKÂERS LOOKÂING TO STYMIE THE COROÂNÂAVIRUS EPIÂDEMÂICYesterday
Coronavirus
Pharma
ENDPOINTS STANDOUTS
HERE ARE THE 52 NEW DRUGS APÂPROVED BY THE FDA IN 2019. WHO WON? WHO LOST? AND WHO JUST SURÂVIVED TO 2020?2 months ago
Pharma
Special
SPEÂCIAL REÂPORT: TWENÂTY EXÂTRAÂORÂDIÂNARY WOMEN IN BIOÂPHARÂMA R&D WHO WORKED THEIR WAY TO THE TOP3 months ago
People
R&D
UNÂLOCK THE FULL ENDÂPOINTS EXÂPEÂRIÂENCE FOR YOUR COMÂPAÂNY — AND SUPÂPORT OUR MISÂSION OF INÂDEÂPENÂDENT BIOÂPHARÂMAREÂPORTÂING
3 months ago
Publisher's note
CELÂEÂBRATÂING TRIÂAL FAILÂURES, CHANGÂING THE CULÂTURE AND ALÂLYÂING WITH CALÂIÂFORÂNIA DREAMÂERS: R&D CHIEFHAL BARÂRON ...
4 months ago
PEER REVIEW SEE ALL
Feb 28
AFÂTER THE FIELD LEFT HER BEÂHIND, A SCIÂENÂTIST-TURNED-INÂVESTOR GETS HER FIRST R&D JOB; NOUSÂCOM FINDS NEW LEADÂERÂSHIP FOR ITSCANÂCER VACÂCINES
Feb 21
ANÂTOÂNIO GUALÂBERÂTO STARTS POST-KUÂRA CAÂREER AT EIÂSAI SUBÂSIDIARY H3; EFÂFECÂTOR CO-FOUNDER SIEGFRIED REÂICH JUMPS TOTURNÂING POINT
Feb 14
PALLEON'S FIRST CSO EXÂPLAINS HOW THEY (AND SHE) GOT HERE; ENÂTERÂPRISE TAPS ROCHE AND NOÂVARÂTIS VET DAVID MORÂRIS AS CMOFeb 7
CRAIG BASÂSON TELLS US WHY HE LEAPT FROM NIÂBR TO BOSTON PHARÂMA; EX-BMS PARTÂNER CYÂTOMX FINDS NEW CMO IN ALÂLIÂSON HANÂNAHJan 31
MODÂERÂNA WOOS TRIÂAL VET MELANIE IVARSÂSON TO THE SEÂNIOR R&D TEAM; EX-ROCHE CMO SANÂDRA HORNÂING JOINS GILEAD BOARDR&D CHANNEL FEED
3 days ago
ENDÂING A GRUÂELÂING 10-YEAR DROUGHT, SANOFI FIÂNALÂLY WINS AN OK FOR AN IN-HOUSE CANÂCER DRUG Sanofi has snagged an FDA apÂproval for a top drug in its pipeline, endÂing a 10-year drought of home-grown canÂcer drug apÂprovals as the new team in charge looks to reÂboot one of the ...READ MORE
KARYOPHARM SPOTÂLIGHTS PHIÂII REÂSULTS AFÂTER CONÂTROÂVERÂSIALFDA APÂPROVAL
3 days ago
Pharma
NEW STUDY SUGÂGESTS IT COSTS $1.3B IN R&D INÂVESTÂMENT TO BRING A DRUG TO MARÂKET. HOW DID IT GET THERE?Yesterday
latest in R&D
AMUÂNIX GRABS $73M FROM FRAÂZIER, OMEGA TO FUÂEL SHIFT TO T CELLENÂGAGERS
Yesterday
BOASTÂING NEW DISÂCOVÂERÂIES FROM XTANÂDI, ERÂLEAÂDA INÂVENÂTORS, ORIC PITCHÂES $86M IPO ON CANÂCER DRUGS TARÂGETÂEDAT REÂSISÂTANCE
2 days ago
FAILÂURE-PRONE UNUM CUTS JOBS, LOSÂES SCIÂENÂTIFÂIC CHIEF, AND CHANGES FOÂCUS YET AGAIN2 days ago
Cell/Gene Tx
BIOÂGEN’S EARÂLY R&D CHIEF EXÂITS FOR ARCH AND BEÂZOS-BACKED ANÂTI-AGÂING BIOTECH2 days ago
IN RECORD-SETÂTING SETÂTLEÂMENT, NOÂVARÂTIS’ SANÂDOZ UNIT ADÂMITS GUILT IN CONÂSPIRÂAÂCY TO FIX PRICES2 days ago
see latest stories
PHARMA CHANNEL FEED
Yesterday
AS COSTS CONÂTINÂUE TO SOAR EVER HIGHÂER, ASÂTRAZENECA SEES NEW HQ STICKÂER PRICE GYÂRATE TO $1.28B AsÂtraZeneca may have come a long ways in changÂing its forÂtunes on the R&D side of the busiÂness, but CEO PasÂcal SoÂriÂot’s 8-year-old dream of buildÂing a globÂal MecÂca for the comÂpaÂnyin ...
READ MORE
THE FDA OKS GENERÂIC DARAÂPRIM, THE MARÂTIN SHKREÂLI THERÂAÂPY THAT TRIGÂGERED AN UNÂENDÂING TEMÂPEST OVER DRUG PRICÂING6 days ago
WHY FDA CAN’T DISÂCLOSE THE FIRST COROÂNÂAVIRUS-REÂLATÂED DRUGSHORTÂAGE
6 days ago
Coronavirus
Regulatory
latest in Pharma
BIOÂHAVEN SCORES CGRP OK FOR ACUTE MIÂGRAINE — CAN THE COMÂMERÂCIAL TEAM CATCH UP WITH ALÂLERÂGAN ON ITS DEÂBUT?Last week
MALLINCKÂRODT, ONCE THE NAÂTION’S LARGEST OXYÂCODONE PROÂDUCÂER, ANÂNOUNCES TENÂTAÂTIVE $1.6B SETÂTLEÂMENTLast week
Deals
NOÂVARÂTIS' PLANS TO WRESÂTLE EYLEA MARÂKET SHARE TAKE A HIT AS BEOVU IS LINKED TO SAFEÂTY CONÂCERNSLast week
Regulatory
SANOFI OUTÂLINES BIG API PLANS AS COROÂNÂAVIRUS OUTÂBREAK REÂPORTÂEDÂLY THREATÂENS SHORTÂAGE OF 150 DRUGSLast week
China
THE FOURTH CGRP MIÂGRAINE DRUG IS HERE. TIME FOR LUNDÂBECK TO PROVEIT'S WORTH $2B
Last week
Regulatory
see latest stories
CORONAVIRUS CHANNEL FEED2 days ago
'UNÂHEARD-OF SPEEDÂS': TRUMP, NEWÂLY WARMED UP TO BIOÂPHARÂMA, PRAISÂES INÂDUSÂTRY'S COROÂNÂAVIRUS REÂSPONSE AT WHITE HOUSEMEETÂING
Speed is of the essence when it comes to deÂvelÂopÂing vacÂcines and therÂaÂpeuÂtics for the new coroÂnÂavirus. EsÂpeÂcialÂly if you are briefÂing PresÂiÂdent DonÂald Trump. “What’s yourtimÂing ...
READ MORE
A 9/11-ERA OMÂAÂHA FAÂCILÂIÂTY, AN OLD EBOÂLA DRUG, AND THE UBIQÂUIÂTOUS DR. FAUÂCI: INÂSIDE THE FIRST US NOVÂELCOROÂNÂAVIRUS ...
Last week
R&D
FOLÂLOWÂING US, CHIÂNA HOSÂPIÂTAL EFÂFORTS, GILEAD PLOTS ITS OWN PHIÂII TRIÂALS FOR CLOSEÂLY WATCHED COVID-19 DRUGLast week
R&D
latest in Coronavirus FDA MONÂIÂTORÂING 20 DRUGS AT RISK OF SHORTÂAGE DUE TOCOROÂNÂAVIRUS
Last week
China
Regulatory
FIRST US COVID-19 TRIÂALS SET TO GET UNÂDERÂWAY IN NEÂBRASÂKA AND WASHÂINGÂTON, BACKED BY NIHLast week
R&D
HARÂVARD JOINS COROÂNÂAVIRUS FIGHT WITH $115M AND A HIGH-PROÂFILECHIÂNESE PARTÂNER
Last week
China
Deals
AS COROÂNÂAVIRUS OUTÂBREAK REACHÂES 'TIPÂPING POINT,' GSK LENDS ADÂJUÂVANT TECH TO CHIÂNESE PARTÂNER ARMED WITH PREÂCLINÂIÂCALVACÂCINE
Last week
China
Deals
CHIÂNA APÂPROVES FLU DRUG BEÂING TOUTÂED AS A POÂTENÂTIAL COROÂNÂAVIRUS TREATÂMENT AMID A RUSH OF CLINÂIÂCAL STUDÂIES3 weeks ago
China
see latest stories
Bioscience & Technology Business Center The University of KansasLawrence, Kansas
LATEST
* All News
* Premium Stories
* Don't Miss
CHANNELS
* Coronavirus
* R&D
* Pharma
* Venture
* People
* Startups
* Regulatory
* Deals
* IPOs
* China
* Cell/Gene Tx
* Bioregnum
* Peer Review
* Discovery
* Outsourcing
* AI
* Special
MORE
* Events
* Webinars
* Sponsored Posts
* Biotech Voices
* Advertise
* About Us
* Help
WORK IN BIOTECH
* Endpoints Careers
© Endpoints Company 2020* Help
* Advertise
* Privacy Policy
* Business Model
SIGN IN TO YOUR ACCOUNTPASSWORD
Change my password Get a magic email linkSIGN IN
REQUEST MAGIC LINK
If you're already an Endpoints subscriber, enter your email below for a MAGIC LINK THAT LETS YOU SIGN IN QUICKLY WITHOUT USING A PASSWORD. Please note the magic link is ONE-TIME USE ONLY and expires after 24hours.
BACK
REQUEST
RESET PASSWORD
We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.BACK
RESET
ABOUT YOU
SUBSCRIPTIONS
ENDPOINTS by John Carroll & team — _all_ the news at 11:30a ET EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ETINSTANT SUBSCRIBE
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0